184.11 USD
+6.02 (+3.38%)
184.5 USD
+0.39 (+0.21%)
We assign a fundamental rating of 7 out of 10 to NUTX. NUTX was compared to 101 industry peers in the Health Care Providers & Services industry. While NUTX has a great health rating, its profitability is only average at the moment. NUTX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! With these ratings, NUTX could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
NUTX had positive earnings in the past year.
NUTX had a positive operating cash flow in the past year.
NUTX had negative earnings in 4 of the past 5 years.
In multiple years NUTX reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 11.83%, NUTX belongs to the top of the industry, outperforming 96.04% of the companies in the same industry.
Looking at the Return On Equity, with a value of 35.96%, NUTX belongs to the top of the industry, outperforming 95.05% of the companies in the same industry.
The Return On Invested Capital of NUTX (38.79%) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.83% | ||
| ROE | 35.96% | ||
| ROIC | 38.79% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 11.63%, NUTX belongs to the top of the industry, outperforming 97.03% of the companies in the same industry.
With an excellent Operating Margin value of 35.72%, NUTX belongs to the best of the industry, outperforming 99.01% of the companies in the same industry.
With a decent Gross Margin value of 55.01%, NUTX is doing good in the industry, outperforming 78.22% of the companies in the same industry.
In the last couple of years the Gross Margin of NUTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.72% | ||
| PM (TTM) | 11.63% | ||
| GM | 55.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NUTX is creating value.
Compared to 1 year ago, NUTX has more shares outstanding
Compared to 5 years ago, NUTX has more shares outstanding
The debt/assets ratio for NUTX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.46 indicates that NUTX is not in any danger for bankruptcy at the moment.
NUTX has a better Altman-Z score (3.46) than 72.28% of its industry peers.
The Debt to FCF ratio of NUTX is 1.87, which is an excellent value as it means it would take NUTX, only 1.87 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.87, NUTX belongs to the top of the industry, outperforming 84.16% of the companies in the same industry.
A Debt/Equity ratio of 0.95 indicates that NUTX is somewhat dependend on debt financing.
NUTX's Debt to Equity ratio of 0.95 is in line compared to the rest of the industry. NUTX outperforms 40.59% of its industry peers.
Even though the debt/equity ratio score it not favorable for NUTX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 1.87 | ||
| Altman-Z | 3.46 |
ROIC/WACC4.68
WACC8.28%
2.3 Liquidity
A Current Ratio of 3.20 indicates that NUTX has no problem at all paying its short term obligations.
NUTX has a Current ratio of 3.20. This is amongst the best in the industry. NUTX outperforms 85.15% of its industry peers.
A Quick Ratio of 3.18 indicates that NUTX has no problem at all paying its short term obligations.
NUTX has a better Quick ratio (3.18) than 86.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.18 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 873.64% over the past year.
The Revenue has grown by 236.03% in the past year. This is a very strong growth!
Measured over the past years, NUTX shows a very strong growth in Revenue. The Revenue has been growing by 222.96% on average per year.
EPS 1Y (TTM)873.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%551.16%
Revenue 1Y (TTM)236.03%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%239.87%
3.2 Future
Based on estimates for the next years, NUTX will show a very strong growth in Earnings Per Share. The EPS will grow by 44.72% on average per year.
NUTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 51.11% yearly.
EPS Next Y78.24%
EPS Next 2Y56.64%
EPS Next 3Y44.72%
EPS Next 5YN/A
Revenue Next Year223.7%
Revenue Next 2Y83.21%
Revenue Next 3Y51.11%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 9.96 indicates a reasonable valuation of NUTX.
Based on the Price/Earnings ratio, NUTX is valued cheaper than 93.07% of the companies in the same industry.
When comparing the Price/Earnings ratio of NUTX to the average of the S&P500 Index (27.00), we can say NUTX is valued rather cheaply.
NUTX is valuated reasonably with a Price/Forward Earnings ratio of 8.60.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NUTX indicates a rather cheap valuation: NUTX is cheaper than 97.03% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of NUTX to the average of the S&P500 Index (23.70), we can say NUTX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.96 | ||
| Fwd PE | 8.6 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NUTX is valued cheaply inside the industry as 96.04% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, NUTX is valued cheaper than 90.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.47 | ||
| EV/EBITDA | 3.81 |
4.3 Compensation for Growth
NUTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NUTX has a very decent profitability rating, which may justify a higher PE ratio.
NUTX's earnings are expected to grow with 44.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.13
PEG (5Y)N/A
EPS Next 2Y56.64%
EPS Next 3Y44.72%
5. Dividend
5.1 Amount
No dividends for NUTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
184.11
+6.02 (+3.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners35.1%
Inst Owner Change0%
Ins Owners2.39%
Ins Owner Change0%
Market Cap1.30B
Revenue(TTM)981.20M
Net Income(TTM)114.07M
Analysts82.22
Price Target255 (38.5%)
Short Float %16.08%
Short Ratio5.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend1.28
Dividend Growth(5Y)N/A
DP39.41%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)298.6%
Min EPS beat(2)-0.77%
Max EPS beat(2)597.97%
EPS beat(4)3
Avg EPS beat(4)2386.61%
Min EPS beat(4)-0.77%
Max EPS beat(4)8939.67%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)15.29%
Min Revenue beat(2)7.78%
Max Revenue beat(2)22.8%
Revenue beat(4)4
Avg Revenue beat(4)79.58%
Min Revenue beat(4)7.78%
Max Revenue beat(4)211.33%
Revenue beat(8)7
Avg Revenue beat(8)41.36%
Revenue beat(12)8
Avg Revenue beat(12)27.1%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.45%
PT rev (3m)3.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)43.7%
EPS NY rev (1m)1.23%
EPS NY rev (3m)352.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.94%
Revenue NY rev (1m)2.16%
Revenue NY rev (3m)12.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.96 | ||
| Fwd PE | 8.6 | ||
| P/S | 1.33 | ||
| P/FCF | 7.47 | ||
| P/OCF | 7.32 | ||
| P/B | 4.1 | ||
| P/tB | 4.62 | ||
| EV/EBITDA | 3.81 |
EPS(TTM)18.49
EY10.04%
EPS(NY)21.42
Fwd EY11.63%
FCF(TTM)24.65
FCFY13.39%
OCF(TTM)25.15
OCFY13.66%
SpS138.78
BVpS44.86
TBVpS39.84
PEG (NY)0.13
PEG (5Y)N/A
Graham Number136.61
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.83% | ||
| ROE | 35.96% | ||
| ROCE | 44.98% | ||
| ROIC | 38.79% | ||
| ROICexc | 49.2% | ||
| ROICexgc | 52.2% | ||
| OM | 35.72% | ||
| PM (TTM) | 11.63% | ||
| GM | 55.01% | ||
| FCFM | 17.76% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
F-Score8
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 1.87 | ||
| Debt/EBITDA | 0.81 | ||
| Cap/Depr | 17% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | 117.8 | ||
| Cash Conversion | 47.91% | ||
| Profit Quality | 152.79% | ||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.18 | ||
| Altman-Z | 3.46 |
F-Score8
WACC8.28%
ROIC/WACC4.68
Cap/Depr(3y)59.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)873.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%551.16%
EPS Next Y78.24%
EPS Next 2Y56.64%
EPS Next 3Y44.72%
EPS Next 5YN/A
Revenue 1Y (TTM)236.03%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%239.87%
Revenue Next Year223.7%
Revenue Next 2Y83.21%
Revenue Next 3Y51.11%
Revenue Next 5YN/A
EBIT growth 1Y1170.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1313.93%
EBIT Next 3Y163.37%
EBIT Next 5YN/A
FCF growth 1Y3319.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2258.27%
OCF growth 3YN/A
OCF growth 5YN/A
NUTEX HEALTH INC / NUTX FAQ
What is the ChartMill fundamental rating of NUTEX HEALTH INC (NUTX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to NUTX.
Can you provide the valuation status for NUTEX HEALTH INC?
ChartMill assigns a valuation rating of 9 / 10 to NUTEX HEALTH INC (NUTX). This can be considered as Undervalued.
What is the profitability of NUTX stock?
NUTEX HEALTH INC (NUTX) has a profitability rating of 6 / 10.
What is the expected EPS growth for NUTEX HEALTH INC (NUTX) stock?
The Earnings per Share (EPS) of NUTEX HEALTH INC (NUTX) is expected to grow by 78.24% in the next year.
How sustainable is the dividend of NUTEX HEALTH INC (NUTX) stock?
The dividend rating of NUTEX HEALTH INC (NUTX) is 0 / 10 and the dividend payout ratio is 39.41%.